On August 26, 2026, the U.S. FDA formally approved Revolution Medicines' RASONQUE (generic name daraxonrasib, development code RMC-6236) for the treatment of adult patients with RAS-mutant metastatic pancreatic ductal adenocarcinoma who have received prior therapy. This is not only the first RAS-targeted drug for pancreatic cancer, but also the first approval of an entirely new drug class: RAS(ON) inhibitors.

One Drug, Three Names

Readers may have seen RMC-6236, daraxonrasib, and RASONQUE in the news — they are actually the same drug: RMC-6236 is the clinical development code, daraxonrasib is the international nonproprietary name, and RASONQUE is the brand name after approval. The approval was based on the Phase 3 RASolute 302 trial: compared with standard chemotherapy, daraxonrasib extended median overall survival from 6.7 months to 13.2 months, reducing the risk of death by about 60%.

Why Is It Called a "Milestone"?

RAS is the most common oncogenic driver gene in solid tumors, and the RAS mutation rate in pancreatic cancer is over 90%. For forty years, the RAS protein was considered "undruggable" because of its smooth surface and lack of a drug-binding pocket. Daraxonrasib uses a "tri-complex" strategy to capture the active form of the RAS protein, covering multiple mutation subtypes at once — essentially opening the door to targeted therapy for the vast majority of pancreatic cancer patients. Analysts widely expect it to quickly become the new standard of care for previously treated pancreatic cancer.

Next Steps and Asian Patients

Before the U.S. approval, the European Medicines Agency (EMA) had already started a rolling review of daraxonrasib and granted it orphan drug designation, with European approval expected to follow. For patients in Asia and Hong Kong, key points to watch include: the drug's registration timeline in Asia, whether it will be included in early access programs, and whether local hospitals have clinical trials enrolling for extended daraxonrasib indications (first-line treatment, lung cancer, colorectal cancer). If you or a family member has a RAS mutation, we recommend discussing the genetic testing report with your oncologist and checking our site for updates to the Hong Kong clinical trial list.